SKUDEXUM 75 mg/25 mg, dexketoprofen/tramadol, Fixed NSAID-weak opioid combination
PAIN - New medicinal product
Opinions on drugs - Posted on Jul 20 2016
Reason for request
- SKUDEXUM has Marketing Authorisation in the short-term symptomatic treatment of moderate to severe acute pain in adult patients whose pain requires a combination of tramadol and dexketoprofen.
- Its analgesic superiority relative to each of its constituents administered as a monotherapy was demonstrated in two studies.
- No comparison with other fixed analgesic combinations is available.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments